ABSTRACT
Mitochondrial µ-calpain and apoptosis-inducing factor (AIF)-dependent photoreceptor cell death has been seen in several rat and mouse models of retinitis pigmentosa (RP). Previously, we demonstrated that the specific peptide inhibitor of mitochondrial µ-calpain, Tat-µCL, protected against retinal degeneration following intravitreal injection or topical eye-drop application in Mertk gene-mutated Royal College of Surgeons rats, one of the animal models of RP. Because of the high rate of rhodopsin mutations in RP patients, the present study was performed to confirm the protective effects of Tat-µCL against retinal degeneration in rhodopsin transgenic S334ter and P23H rats. We examined the effects of intravitreal injection or topical application of the peptide on retinal degeneration in S334ter and P23H rats by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay, electroretinogram (ERG), immunohistochemistry for AIF, and histological staining. In S334ter rats, we found that intravitreal injection or topical application of the peptide prevented photoreceptor cell death from postnatal (PN) 15 to 18 days, the time of early-stage retinal degeneration. Topical application of the peptide also delayed attenuation of ERG responses from PN 28 to 56 days. In P23H rats, topical application of the peptide protected against photoreceptor cell death and nuclear translocation of AIF on PN 30, 40, and 50 days, as the primary stages of degeneration. We observed that topical application of the peptide inhibited the thinning of the outer nuclear layer and delayed ERG attenuations from PN 30 to 90 days. Our results demonstrate that the mitochondrial µ-calpain and AIF pathway is involved in early-stage retinal degeneration in rhodopsin transgenic S334ter and P23H rats, and inhibition of this pathway shows curative potential for rhodopsin mutation-caused RP.
Subject(s)
Apoptosis Inducing Factor/antagonists & inhibitors , Calpain/antagonists & inhibitors , Mitochondrial Proteins/antagonists & inhibitors , Peptides/pharmacology , Photoreceptor Cells, Vertebrate/drug effects , Retinitis Pigmentosa/drug therapy , Animals , Apoptosis Inducing Factor/genetics , Apoptosis Inducing Factor/metabolism , Calpain/genetics , Calpain/metabolism , Cell Death/drug effects , Cell Nucleus/drug effects , Cell Nucleus/metabolism , Disease Models, Animal , Electroretinography , Gene Expression Regulation , In Situ Nick-End Labeling , Intravitreal Injections , Mitochondria/drug effects , Mitochondria/metabolism , Mitochondrial Proteins/genetics , Mitochondrial Proteins/metabolism , Mutation , Ophthalmic Solutions , Peptides/chemical synthesis , Photoreceptor Cells, Vertebrate/metabolism , Photoreceptor Cells, Vertebrate/pathology , Protein Transport/drug effects , Rats , Rats, Transgenic , Retinitis Pigmentosa/genetics , Retinitis Pigmentosa/metabolism , Retinitis Pigmentosa/pathology , Rhodopsin/genetics , Rhodopsin/metabolism , Signal TransductionABSTRACT
Mitochondrial µ-calpain initiates apoptosis-inducing factor (AIF)-dependent apoptosis in retinal photoreceptor degeneration. Mitochondrial µ-calpain inhibitors may represent therapeutic targets for the disease. Therefore, we sought to identify inhibitors of mitochondrial calpains and determine their effects in Royal College of Surgeons' (RCS) rats, an animal model of retinitis pigmentosa (RP). We synthesized 20-mer peptides of the C2-like (C2L) domain of µ-calpain. Two µ-calpain peptides N2 and N9 inhibited mitochondrial µ-calpain activity (IC(50); 892 and 498nM, respectively), but not other proteases. Western blotting showed that 50µM of both µ-calpain peptides caused specific degradation of mitochondrial µ-calpain. Three-dimensional structure of calpains suggested that the peptides N2 and N9 corresponded to the regions forming salt bridges between the protease core domain 2 and the C2L domain. We determined the inhibitory regions of µ-calpain peptides N2 and N9 using 10-mers, and one peptide, N2-10-2, inhibited the activity of mitochondrial µ-calpain (IC(50); 112nM). We next conjugated the peptide N2-10-2 to the C-terminal of HIV-1 tat (HIV), a cell-penetrating peptide. Using isolated rat liver mitochondria, 50µM HIV-conjugated µ-calpain N2-10-2 peptide (HIV-Nµ, IC(50); 285nM) significantly inhibited AIF truncation. The intravitreal injection of 20mM HIV-Nµ also prevented retinal photoreceptor apoptosis determined by TUNEL staining, and preserved retinal function assessed by electroretinography in RCS rats. Topical application of 40mM HIV-Nµ also prevented apoptosis of retinal photoreceptors in RCS rats. Our results demonstrate that HIV-Nµ, a peptide inhibitor of mitochondrial µ-calpain, offers a new modality for treating RP.
